(Q40505693)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Josef Wissing

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Klaus Godl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Dirk Brehmer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Stephanie Blencke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Martina Weber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Peter Habenberger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Matthias Stein-Gerlach

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Andrea Missio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Stefan Müller

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Henrik Daub

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

8 October 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

Molecular & Cellular Proteomics

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

1181-1193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

Protein kinases--the major drug targets of the twenty-first century?

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Rediscovering the sweet spot in drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Exploiting features of adenovirus replication to support mammalian kinase production

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Optimization of guanidination procedures for MALDI mass mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Identification of tyrosine 67 in bovine brain myelin basic protein as a specific phosphorylation site for thymus p56lck

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

An analysis of the proteomic profile for Thermoanaerobacter tengcongensis under optimal culture conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Involvement of receptor-interacting protein 2 in innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha ) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Beyond Herceptin and Gleevec

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M400124-MCP200

10.1074/MCP.M400124-MCP200

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15475568%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference